Core Insights - Barinthus Biotherapeutics plc is advancing its clinical trials and has reported financial results for Q3 2024, highlighting significant progress in its pipeline, particularly in chronic hepatitis B and celiac disease treatments [1][2]. Clinical Developments - The company completed enrollment in the HBV003 trial of VTP-300 for chronic hepatitis B with 121 adult participants, aiming for a potential functional cure [3]. - Interim data from the HBV003 trial showed that 76% of participants met criteria for nucleos(t)ide analogue therapy discontinuation, with 19% achieving undetectable HBsAg levels [4]. - The first-in-human Phase 1 AVALON trial of VTP-1000 for celiac disease was initiated, focusing on safety and pharmacokinetics [5]. - Enrollment for the PCA001 trial of VTP-850 in prostate cancer was completed with 22 participants, with data expected in the first half of 2025 [6]. Financial Performance - As of September 30, 2024, the company reported cash and equivalents of $106.1 million, down from $117.8 million at the end of Q2 2024, with a net cash usage of $18.2 million in Q3 [9]. - Revenue for Q3 2024 was $15.0 million, attributed to royalties from Oxford University Innovation, compared to no revenue in Q2 2024 [9]. - Research and development expenses decreased to $11.1 million in Q3 2024 from $11.7 million in Q2 2024, primarily due to reduced personnel costs [9][10]. - General and administrative expenses rose to $13.4 million in Q3 2024, largely due to a foreign exchange loss of $7.7 million [12]. - The net loss for Q3 2024 was $8.1 million, or $(0.21) per share, an improvement from a net loss of $16.9 million in Q2 2024 [12][19]. Upcoming Milestones - Updated data from the VTP-300 program is expected in Q4 2024, with presentations at the AASLD – The Liver Meeting® 2024 [7]. - Data from the Phase 1 AVALON trial of VTP-1000 is anticipated in the first half of 2025 [8]. - Results from the Phase 1 PCA001 trial of VTP-850 are also expected in the first half of 2025 [8].

Table of Contents (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________to ________ Commission File Number: 001-40367 BARINTHUS BIOTHERAPEUTICS PLC (Exact Name of Registrant as Specified in its Charter) Engl ...

Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results OXFORD, United Kingdom, August 8, 2024 (GLOBE NEWSWIRE) – Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinicalstage biopharmaceutical company developing novel T cell immunotherapeutic candidates, provided an overview of the Company's progress and announced its financial results for the second quarter of 2024. "Following the positive VTP-300 Phase 2 data in hepatitis B virus (HBV) in the second quarter, we ma ...

SAN MATEO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Anne Phillips and Jennifer Jarrett, to the board of directors of the Company, effective August 1, 2024. "We are thrilled to welcome Anne and Jennifer to our board as we prep ...

OXFORD, United Kingdom, June 12, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates, today announced plans to prioritize its pipeline to focus on the development of VTP-300 in CHB and VTP-1000 in celiac disease. The development of VTP-300 in CHB and VTP-1000 in celiac disease will be prioritized and the ongoing Phase 1 clinical trial of VTP-850 in prostate cancer will be completed. The Company ...

The development of VTP-300 in chronic Hepatitis B (CHB) and VTP-1000 in celiac disease will be prioritized. The pipeline prioritization is expected to result in a reduction in workforce of approximately 25% and an estimated extension to the cash runway into the second quarter of 2026. The decision follows the positive interim data from the two ongoing Phase 2 clinical trials presented at the European Association for the Study of the Liver (EASL) Congress on June 6, 2024. The data from the ongoing HBV003 and ...

In the HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation. In the IM-PROVE II trial, conducted in partnership with Arbutus Biopharma, a statistically significant difference was observed in HBsAg levels between the VTP-300 treatment and placebo groups at 24- weeks post-end of treatment (EOT) and 84% ...

Even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditure to develop and market additional product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other factors that may adversely affect our business. The size of our future net losses will depend on the rate of future growth of our expenses combined with our ability to generate revenue. Our prior losses and expect ...

Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments "So far in 2024 we have continued to make strides across our programs. Notably, we received clearance from the FDA on an IND to progress VTP-1000 in a first in human clinical trial in celiac disease, as well as clearance from the Australian Ethics Committee on this trial. We expect to begin our Phase 1 trial of VTP-1000 in participants with celiac disease in the coming months. Additionally, we reported topline fi ...

OXFORD, United Kingdom, May 13, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer, announced its financial results for the first quarter of 2024 and provided an overview of the Company's progress. "So far in 2024 we have continued to make strides across our programs. Notably, we received clear ...